IP Library Granted Patent US 8,735,579
Granted Patent B2
US 8,735,579 · App. 13/060,761 · Granted May 27, 2014

Benzamides, production thereof, and use thereof as medicaments

Inventors: Holger Wagner (Mettenberg, DE); Elke Langkopf (Warthausen, DE); Frank Himmelsbach (Mittelbiberach, DE); Rolf Goeggel (Ulm, DE); Birgit Jung (Laupheim, DE)
Assignee: Boehringer Ingelheim International GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,735,579
App. No.
13/060,761
Granted
May 27, 2014
Kind
B2
Abstract

Heteroaryloxy-substituted benzoic acid amides of general formula I wherein the groups R 1 to R 7 as well as X and Y are defined according to claim 1 , including the tautomers, the stereoisomers, the mixtures and the salts thereof. The compounds according to the invention are suitable for the treatment of respiratory complaints, particularly COPD and asthma.

Claims (214)

1. A compound of the formula I

wherein

R 1 is L 1 -R 8 ,

where L 1 is selected from a bond, O, CO, NH, CONH, NHCO, SO, SO 2 , SO 2 NH, NHSO 2 and C 1 -C 4 -alkylene,

where R 8 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 -alkynyl, C 2-6 -alkenyl, C 3-8 -cycloalkyl, C 3-8 -heterocycloalkyl, C 6-10 -aryl, C 5-10 -heteroaryl, cyano, carboxy, C 1-4 -alkyloxycarbonyl, nitro, amino, di-(C 1-4 -alkyl)-amino, hydroxy, C 1-6 -alkylsulphanyl,

R 8 may be partly or completely fluorinated and/or may be substituted by one or more substituents L, and

wherein in heterocycloalkyl groups a methylene group may be substituted by CO, SO or SO 2 , and

wherein R 1 is not hydrogen if R 3 denotes hydrogen, and

R 2 is L 2 -R 9 ,

wherein L 2 is selected from a bond, O, CO, NH, CONH, NHCO, SO, SO 2 , SO 2 NH, NHSO 2 and C 1 -C 4 -alkylene

wherein R 9 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 -alkynyl, C 2-5 -alkenyl, C 3-8- cycloalkyl, C 4-8 -cycloalkenyl, C 3-8 -heterocycloalkyl, C 6-10 -aryl, C 5-10 -heteroaryl, cyano, carboxy, C 1-4 -alkyloxycarbonyl, nitro, amino, di-(C 1-4 -alkyl)-amino, hydroxy, C 1-6 -alkylsulphanyl,

wherein R 9 may be partly or completely fluorinated and/or may be substituted by one or more substituents L, and

wherein in the alkyl groups mentioned optionally one or two CH 2 groups may be exchanged for O and/or NR N ,

wherein in the cycloalkyl groups mentioned one or two CH 2 groups may be replaced independently of one another by NR N , O, S, CO, SO or SO 2 and one or two CH groups may be replaced by N, and

R 3 is L 3 -R 10

wherein L 3 is selected from a bond, O, CO, NH, CONH, NHCO, SO, SO 2 , SO 2 NH, NHSO 2 and C 1 -C 4 -alkylene

wherein R 10 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 -alkynyl, C 2-6 -alkenyl, C 3-8 -cycloalkyl, C 4-8 -cycloalkenyl, C 3-8 -heterocycloalkyl, C 5-10 -aryl, C 5-10 -heteroaryl, cyano, carboxy, C 1-4 -alkyloxycarbonyl, nitro, amino, di-(C 1-4 -alkyl)-amino, hydroxy, C 1-6 -alkylsulphanyl

wherein R 10 may be partly or completely fluorinated and/or may be substituted by one or more substituents L, and

wherein R 3 is not hydrogen if R 1 denotes hydrogen,

R 4 is L 4 -R 11

wherein L 4 is selected from a bond, O, CO, NH, CONH, NHCO,

wherein R 11 is selected from hydrogen, halogen, amino, C 1-6 -alkyl, C 3-8 -cycloalkyl, C 3-8 -heterocycloalkyl, trifluoromethyl, difluoromethyl, cyano, carboxy, C 1-4 -alkyloxycarbonyl, di-(C 1-4 -alkyl)-amino, C 1-4 -alkylsulphanyl,

R 5 is C 1-6 -alkyl,

R 6 is

dimethylamino-C 1-3 -alkyl, cyclopropylamino-C 1-3 -alkyl, pyrrolidinyl-C 1-3 -alkyl, hydroxy-C 1-3 -alkyl, methylsulphanyl-C 1-3 -alkyl, methylsulphinyl-C 1-3 -alkyl, methylsulphonyl-C 1-3 -alkyl, C 1-4 -alkylcarbonylamino, C 3-5 -cycloalkyl-carbonylamino, C 1-4 -alkylsulphonylamino, C 3-5 -cycloalkylsulphonylamino, C 1-3 -alkylsulphinyl and C 1-3 -alkylsulphonyl

R 7 is C 1-6 -alkyl, trifluoromethyl, pentafluoroethyl,

X,Y independently of one another denote N or C—R 13 , wherein one of X and Y is N and the other is C—R 13 and R 13 is selected from hydrogen, fluorine, chlorine, C 1-4 -alkyl, trifluoromethyl, OH, C 1-4 -alkyloxy, trifluoromethoxy, difluoromethoxy and cyano,

R N is selected from H, C 1-4 -alkyl, 1,1,1-trifluoroethyl, cyanmethyl, acetyl, methylsulphonyl, C 6-10 -arylmethyl,

L is selected from among halogen, cyano, C 1-6 -alkyl, C 1-6 -alkyloxy, amino, C 1-3 -alkylamino, di-(C 1-3 -alkyl)-amino, C 1-4 -alkylcarbonylamino, difluoromethyl, C 1-4 -alkylsulphonylamino trifluoromethyl, hydroxy, C 1-3 -alkoxy, difluoromethoxy, trifluoromethoxy, acetylamino, C 6-10 -aryl and C 5-10 -heteroaryl.

2. The compound according to claim 1

wherein

R 1 is selected from hydrogen, halogen, C 1-6 -alkyl, C 2-6 -alkynyl, C 2-5 -alkenyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-3 -alkyl, C 6-10 -aryl, C 5-10 -heteroaryl, C 6-10 -aryl-C 1-3 -alkyl, C 5-10 -heteroaryl-C 1-3 -alkyl, C 1-4 -alkylcarbonyl, cyano, aminocarbonyl, C 1-4 -alkyl-aminocarbonyl, di-(C 1-3 -alkyl)-aminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-(C 1-4 -alkyl)-piperazin-1-ylcarbonyl, carboxy, C 1-4 -alkyloxycarbonyl, nitro, amino, C 1-4 -alkylamino, di-(C 1-3 -alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-(C 1-4 -alkyl)piperazin-1-yl, C 1-4 -alkylcarbonylamino, C 1-4 -alkylsulphonylamino, hydroxy, C 1-6 -alkyloxy, C 3-7 -cycloalkyloxy, C 6-10 -aryloxy, C 1-4 -alkylsulphanyl, C 1-4 -alkylsulphinyl and C 1-4 -alkylsulphonyl,

wherein alkyl, alkenyl, alkynyl, cycloalkyl and heterocycloalkyl groups may be partly or completely fluorinated and/or mono- or disubstituted by identical or different substituents selected from cyano, hydroxy, C 1-3 -alkyloxy, acetylamino, methylsulphonylamino and C 1-3 -alkyl, and

wherein in cycloalkyl groups one or two methylene groups may be substituted independently of one another by O, S, CO, SO or SO 2 , and

wherein in N-heterocycloalkyl groups a methylene group may be substituted by CO or SO 2 ,

wherein R 1 is not hydrogen if R 3 denotes hydrogen, and

R 2 is selected from hydrogen, C 1-8 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-7 -cycloalkyl-C 1-4 -alkyl, C 1-6 -alkylcarbonyl-C 1-3 -alkyl, C 6-10 -aryl-C 1-4 -alkyl, C 5-10 -heteroaryl-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 1-6 -alkylcarbonyl, C 3-7 -cycloalkyl-carbonyl, cyano, aminocarbonyl, carboxy, amino, C 1-4 -alkylcarbonylamino, C 1-4 -alkylsulphonylamino, C 1-4 -alkyloxy, C 6-10 -aryl, C 5-10 -heteroaryl, hydroxy,

wherein all the above-mentioned alkyl, alkenyl, alkynyl and cycloalkyl groups may be partly or completely fluorinated and/or mono-, di- or trisubstituted by identical or different substituents selected from C 1-3 -alkyl, cyano, hydroxy, C 1-3 -alkyloxy, amino, C 1-3 -alkylamino, di-(C 1-3 -alkyl)amino, acetylamino, methylsulphonylamino, C 6-10 -aryl and C 5-10 -heteroaryl,

wherein in the alkyl groups mentioned one or two CH 2 groups may optionally be exchanged for O and/or NR N ,

wherein in the cycloalkyl groups mentioned one or two CH 2 groups may be replaced independently of one another by NR N , O, S, CO, SO or SO 2 and one or two CH groups may be replaced by N, and

R 3 is selected from hydrogen, halogen, C 1-4 -alkyl, C 2-6 -alkynyl, C 2-6 -alkenyl, C 3-7 -cycloalkyl-C 1-3 -alkyl, C 3-6 -cycloalkyl, trifluoromethyl, difluoromethyl, hydroxy, C 1-4 -alkyloxy, trifluoromethoxy, difluoromethoxy, cyano, aminocarbonyl, C 1-4 -alkyl-aminocarbonyl, di-(C 1-3 -alkyl)-aminocarbonyl, carboxy, C 1-4 -alkyloxycarbonyl, amino, C 1-4 -alkylamino, di-(C 1-3 -alkyl)-amino, C 1-4 -alkylcarbonylamino, C 1-4 -alkylsulphonylamino, wherein R 3 is not hydrogen if R 1 denotes hydrogen,

R 4 is selected from hydrogen, C 1-4 -alkyl, C 3-6 -cycloalkyl, trifluoromethyl, difluoromethyl, cyano, carboxy, aminocarbonyl, C 1-3 -alkylaminocarbonyl, di-(C 1-3 -alkyl)aminocarbonyl, C 1-4 -alkyloxycarbonyl, amino, C 1-3 -alkylamino, di-(C 1-3 -alkyl)amino, hydroxy, C 1-4 -alkyloxy, C 1-4 -alkylsulphanyl,

R 5 is C 1-4 -alkyl,

R 6 is selected from

dimethylaminomethyl, cyclopropylaminomethyl, pyrrolidin-1-ylamino, hydroxymethyl, methylsulphanylmethyl, methylsulphinylmethyl, methylsulphonylmethyl, n-butylcarbonyl-amino, isopropylcarbonyl-amino, isobutylcarbonylamino, cyclopropylcarbonylamino, methylsulphonylamino, isopropylsulphonylamino, n-butylsulphonylamino, isobutylsulphonyl-amino, cyclopropyl-sulphonylamino, methylsulphinyl and methylsulphonyl,

R 7 is selected from C 4 -alkyl, trifluoromethyl, pentafluoroethyl,

R 13 is selected from hydrogen, fluorine, chlorine, C 1-4 -alkyl, trifluoromethyl, hydroxy, C 1-4 -alkyloxy, trifluoromethoxy, difluoromethoxy, cyano,

R N is selected from H, C 1-4 -alkyl, 1,1,1-trifluoroethyl, cyanomethyl, acetyl, methylsulphonyl, C 6-10 -arylmethyl,

L selected from among fluorine, chlorine, bromine, C 1-3 -alkyl, difluoromethyl, trifluoromethyl, hydroxy, C 1-3 -alkoxy, difluoromethoxy, trifluoromethoxy, acetylamino, methylsulphonylamino and cyano,

wherein by the C 5-10 -aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, which may be mono- or disubstituted independently of one another by identical or different groups L; and

by the heteroaryl groups mentioned in the definition of the above-mentioned groups are meant a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group,

or a pyrrolyl, furanyl, thienyl or pyridyl group is meant, wherein one or two methyne groups are replaced by nitrogen atoms,

or an indolyl, benzofuranyl, benzothiophenyl, quinolinyl or isoquinolinyl group is meant, wherein one to three methyne groups are replaced by nitrogen atoms,

wherein the above-mentioned heteroaryl groups may be mono- or disubstituted independently of one another by identical or different groups L;

wherein, unless stated otherwise, the above-mentioned alkyl groups may be straight-chain or branched,

the tautomers, the stereoisomers, the mixtures and the physiologically acceptable salts thereof.

3. The compound according to claim 2 wherein

R 1 is selected from hydrogen, fluorine, chlorine, bromine, C 1-4 -alkyl, trifluoromethyl, C 3-6 -cycloalkyl, cyano, aminocarbonyl, C 1-4 -alkyl-aminocarbonyl, di-(C 1-3 -alkyl)-aminocarbonyl, carboxy, C 1-4 -alkyloxycarbonyl, amino, C 1-4 -alkylamino, di-(C 1-3 -alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, acetylamino, methylsulphonylamino, hydroxy, C 1-4 -alkyloxy, trifluoromethoxy, difluoromethoxy and C 1-4 -alkylsulphonyl,

wherein the above-mentioned alkyl, cycloalkyl and N-heterocycloalkyl groups may be mono- or disubstituted by identical or different substituents selected from cyano, hydroxy, C 1-3 -alkyloxy, acetylamino, methylsulphonylamino and C 1-3 -alkyl, and wherein in the cycloalkyl groups mentioned one or two methylene groups may be substituted independently of one another by 0, CO or SO 2 and in the above-mentioned N-heterocycloalkyl groups a methylene group may be substituted by CO or SO 2 , and

wherein R 1 is not hydrogen if R 3 denotes hydrogen.

4. The compound according to claim 3 wherein

R 1 is selected from hydrogen, fluorine, chlorine, bromine, C 1-4 -alkyl, trifluoromethyl, C 3-6 -cycloalkyl, cyano, aminocarbonyl, C 1-4 -alkyl-aminocarbonyl, di-(C 1-3 -alkyl)-aminocarbonyl, carboxy, C 1-4 -alkyloxycarbonyl, amino, C 1-4 -alkylamino, di-(C 1-3 -alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, acetylamino, methylsulphonylamino, hydroxy, C 1-4 -alkyloxy, trifluoromethoxy, difluoromethoxy and C 1-4 -alkylsulphonyl, wherein R 1 is not hydrogen if R 3 denotes hydrogen.

5. The compound according to claim 4 wherein R 1 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl and trifluoromethyl, wherein R 1 is not hydrogen if R 3 denotes hydrogen.

6. The compound according to claim 5 wherein

R 2 is selected from hydrogen, C 1-4 -alkyl, C 3-6 -cycloalkyl-C 1-3 -alkyl, C 3-6 -cycloalkylamino-C 1-3 -alkyl, pyrrolidinyl-C 1-3 -alkyl, piperidin-C 1-3 -alkyl, azepanyl-C 1-3 -alkyl, piperazinyl-C 1-3 -alkyl, morpholinyl-C 1-3 -alkyl, homopiperazinyl-C 1-3 -alkyl, pyrrolidin-3-ylamino-C 1-3 -alkyl, piperidin-3-ylamino-C 1-3 -alkyl, piperidin-4-ylamino-C 1-3 -alkyl, C 3-6 -cycloalkyl, trifluoromethyl,

cyano, aminocarbonyl, C 1-4 -alkyl-aminocarbonyl, di-(C 1-3 -alkyl)-aminocarbonyl, piperazin-1-ylcarbonyl, morpholin-4-ylcarbonyl, carboxy, C 1-4 -alkyloxycarbonyl,

amino, C 1-4 -alkylamino, C 3-6 -cycloalkylamino, C 3-6 -cycloalkyl-C 1-3 -alkylamino, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, C 1-3 -alkyl-amino-C 2-3 -alkylamino, pyrrolidin-3-ylamino, piperidin-3-ylamino, piperidin-4-ylamino, pyrrolidinyl-C 1-3 -alkyl-amino, piperidin-C 1-3 -alkyl-amino, piperazinyl-C 1-3 -alkyl-amino, morpholinyl-C 1-3 -alkyl-amino, homopiperazinyl-C 1-3 -alkyl-amino, acetylamino, methylsulphonylamino,

hydroxy, C 1-4 -alkyloxy, trifluoromethoxy, difluoromethoxy, C 3-6 -cycloalkyloxy, C 3-6 -cycloalkyl-C 1-3 -alkyloxy, C 1-3 -alkylamino-C 2-3 -alkyloxy, di-(C 1-3 -alkyl)-amino-C 2-3 -alkyloxy, pyrrolidinyl-C 2-3 -alkyloxy, piperidin-C 2-3 -alkyloxy, piperazinyl-C 2-3 -alkyloxy, morpholinyl-C 2-3 -alkyloxy, homopiperazinyl-C 2-3 -alkyloxy,

wherein the above mentioned alkyl, cycloalkyl and N-heterocycloalkyl groups may be mono- or disubstituted by identical or different substituents selected from C 1-3 -alkyl, cyano, amino, C 1-3 -alkylamino, di-(C 1-3 -alkyl)amino, acetylamino, methylsulphonylamino, hydroxy and C 1-3 -alkyloxy, and

wherein in the above mentioned cycloalkyl groups one or two methylene groups may be substituted independently of one another by O and/or CO and in the above-mentioned N-heterocycloalkyl groups a methylene group may be substituted by CO or SO 2 , and wherein optional all the NH groups contained in the above mentioned groups are replaced by N-Me, N-Et, N-acetyl and N—SO 2 Me.

7. The compound according to claim 5 wherein

R 2 is selected from hydrogen, C 1-4 -alkyl, C 1-3 -alkylamino-C 1-3 -alkyl, tetrahydrofuran-3-ylamino-C 1-3 -alkyl, pyrrolidinyl-C 1-3 -alkyl, piperidinyl-C 1-3 -alkyl, azepanyl-C 1-3 -alkyl, piperazinyl-C 1-3 -alkyl, 4-(1,1,1-trifluoroethyl)-piperazin-1-yl-C 1-3 -alkyl, 4-cyanomethyl-piperazin-1-yl-C 1-3 -alkyl, homopiperazinyl-C 1-3 -alkyl, morpholinyl-C 1-3 -alkyl, N-(pyrrolidin-3-yl)-N—(C 1-3 -alkyl)-amino-C 1-3 -alkyl, pyrrolidin-3-ylamino-C 1-3 -alkyl, N-[di-(C 1-3 -alkyl)amino-C 2-3 -alkyl]-N—(C 1-3 -alkyl)-amino-C 1-3 -alkyl, N-[di-(C 1-3 -alkyl)amino-C 2-3 -alkyl]-amino-C 1-3 -alkyl, N-(piperidinyl)-N—(C 1-3 -alkyl)-amino-C 1-3 -alkyl, piperidinylamino-C 1-3 -alkyl, C 1-3 -alkyl-aminocarbonyl, piperazin-1-ylcarbonyl, morpholin-4-ylcarbonyl, amino, C 1-3 -alkylamino, C 5-6 -cycloalkylamino, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, pyrrolidin-3-ylamino, N—(C 1-3 -alkyl)-N-(pyrrolidin-3-yl)-amino, piperidin-4-ylamino, N—(C 1-3 -alkyl)-N-(piperidin-4-yl)-amino, di-(C 1-3 -alkyl)-amino-C 2-3 -alkylamino, N-[di-(C 1-3 -alkyl)-amino-C 2-3 -alkyl]-N—(C 1-3 -alkyl)-amino, pyrrolidin-1-yl-C 2-3 -alkyl-amino, hydroxy-C 2-3 -alkyl-amino, hydroxy,

wherein in the above-mentioned N- and O-heterocycloalkyl groups a CH 2 group is optionally replaced by C═O and each of these cyclic groups is optionally substituted by a group selected from C 1-3 -alkyl, amino, C 1-3 -alkyl-amino, di-(C 1-3 -alkyl)-amino and hydroxy.

8. The compound according to claim 5 wherein

R 2 is selected from hydrogen, methyl, methylaminomethyl, 3-hydroxypyrrolidin-1-ylmethyl, 3-dimethylaminopyrrolidin-1-ylmethyl, N-(1-methylpyrrolidin-3-yl)-N-methyl-aminomethyl, piperidin-4-ylmethyl, N-methyl-piperidin-4-ylmethyl, azepan-4-ylmethyl, 1-methyl-azepan-4-ylmethyl, N-(2-dimethylaminoethyl)-N-methyl-aminomethyl, N-(2-dimethyl-aminoethyl)-aminomethyl, N-(1-methylpyrrolidin-3-yl)-aminomethyl, 1-methylpiperidin-4-ylaminomethyl, 1-methylpiperidin-3-yl-aminomethyl, piperazin-1-ylmethyl, 4-methyl-piperazin-1-ylmethyl, 4-(1,1,1-trifluoroethyl)-piperazin-1-ylmethyl, 4-cyanomethyl-piperazin-1-ylmethyl, piperazin-2-one-4-ylmethyl, morpholin-4-ylmethyl, tetrahydrofuran-3-ylaminomethyl, homo-piperazin-1-ylmethyl, 4-methylhomopiperazin-1-ylmethyl, methylaminocarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, morpholin-4-ylcarbonyl, methylamino, 4-dimethylaminocyclohexyl-amino, 3-dimethyl-amino-pyrrolidin-1-yl, pyrrolidin-3-ylamino, N-methyl-N-pyrrolidin-3-yl-amino, N-methyl-N-(1-methylpyrrolidin-3-yl)-amino, piperidin-4-ylamino, 1-methyl-piperidin-4-ylamino, N-methyl-N-piperidin-4-yl-amino, 4-dimethylamino-piperidin-1-yl, piperazin-1-yl, piperazin-2-one-4-yl, morpholin-4-yl, 2-(dimethylamino)ethyl-amino, 2-(pyrrolidin-1-yl)ethylamino, 2-hydroxy-ethylamino, N-(2-dimethylaminoethyl)-N-methyl-amino, hydroxy.

9. The compound according to claim 8 wherein

R 3 is selected from hydrogen, C 1-3 -alkyl, C 3-6 -cycloalkyl, fluorine, chlorine, bromine, trifluoromethyl, difluoromethyl, hydroxy, C 1-3 -alkyloxy, trifluoromethoxy, difluoromethoxy and cyano, wherein R 3 is not hydrogen if R 1 denotes hydrogen.

10. The compound according to claim 8 wherein

R 3 is selected from hydrogen, C 1-3 -alkyl, fluorine, chlorine, trifluoromethyl, C 1-3 -alkyloxy and cyano, wherein R 3 is not hydrogen if R 1 denotes hydrogen.

11. The compound according to claim 8 wherein R 3 is selected from hydrogen, methyl, fluorine and chlorine, wherein R 3 is not hydrogen if R 1 denotes hydrogen.

12. The compound according to claim 11 wherein R 4 is selected from hydrogen, C 1-3 -alkyl, trifluoromethyl, carboxy, aminocarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, amino, C 1-3 -alkylamino, di-(C 1-3 -alkyl)-amino, hydroxy and C 1-3 -alkyloxy.

13. The compound according to claim 11 wherein R 4 is selected from hydrogen, methyl, dimethylamino, hydroxy and methoxy.

14. The compound according to claim 11 wherein R 4 is hydrogen.

15. The compound according to claim 13 wherein R 5 is selected from methyl, ethyl, n-propyl and isopropyl.

16. The compound according to claim 14 wherein R 5 is selected from methyl, ethyl and isopropyl.

17. The compound according to claim 14 wherein R 5 is methyl.

18. The compound according to claim 17 wherein R 6 is methylsulphonylamino.

19. The compound according to claim 18 wherein R 7 is selected from isobutyl, tert-butyl, trifluoromethyl and pentafluoroethyl.

20. The compound according to claim 18 wherein R 7 is selected from tert-butyl, trifluoromethyl and pentafluoroethyl.

21. The compound according to claim 18 wherein R 7 is tert-butyl.

22. The compound according to claim 21 wherein

X and Y are selected independently of one another from N, C—H, C—F, C—Cl, C—C 1-3 -alkyl and C 1-3 -alkyloxy.

23. The compound according to claim 21 X and Y are selected independently of one another from N, C—H, C—F and C-Me.

24. The compound according to claim 21 X and Y are N and CH or CH and N.

25. A compound chosen from

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(2-methylamino-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-methylamino-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(2-pyrrolidin-1-yl-ethylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[6-(2-hydroxy-ethylamino)-pyrimidin-4-yloxy]-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[6-(2-dimethylamino-ethylamino)-pyrimidin-4-yloxy]-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(3-oxo-piperazin-1-yl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-pyrrolidin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-morpholin-4-yl-pyrimidin-4-yloxy)-benzamide;

(R)—N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[2-(3-dimethylamino-pyrrolidin-1-yl)-pyrimidin-4-yloxy]-4-methyl-benzamide;

(S)—N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[2-(3-dimethylamino-pyrrolidin-1-yl)-pyrimidin-4-yloxy]-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[2-(4-dimethylamino-piperidin-1-yl)-pyrimidin-4-yloxy]-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(1-methyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(piperazine-1-carbonyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[6-(piperazine-1-carbonyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-(2-piperazin-1-yl-pyrimidin-4-yloxy)-4-trifluoromethyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-Phenyl)-4-methyl-3-(2-piperazin-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-piperazin-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methoxy-3-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-fluoro-3-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-bromo-3-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-chloro-4-methyl-5-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-fluoro-4-methyl-5-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(N-methyl-N-piperidin-4-yl-amino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-ethyl-5-(2-piperazin-1-yl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-piperidin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(2-piperidin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-methyl-5-[2-(piperazine-1-carbonyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-methyl-5-(2-piperazin-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

6-[5-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenylaminocarbonyl)-2-methyl-phenoxy]-pyrimidin-4-carboxylic acid-methylamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(morpholine-4-carbonyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(4-methyl-piperazine-1-carbonyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-morpholin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-methylaminomethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(2-morpholin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(2-methylaminomethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(3-oxo-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(3-oxo-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(6-piperazin-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(4-methyl-homopiperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-{2-[(1-methyl-piperidin-4-ylamino)-methyl]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-{2-[(1-methyl-piperidin-3-ylamino)-methyl]pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-(2-{[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-methyl}-pyrimidin-4-yloxy)-benzamide;

(S)—N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[2-(3-dimethylamino-pyrrolidin-1-ylmethyl)-pyrimidin-4-yloxy]-4-methyl-benzamide;

(R)—N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[2-(3-dimethylamino-pyrrolidin-1-ylmethyl)-pyrimidin-4-yloxy]-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-{2-[(1-methyl-pyrrolidin-3-ylamino)-methyl]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-(2-{[N-(2-dimethylamino-ethyl)-N-methyl-amino]-methyl}-pyrimidin-4-yloxy)-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-{2-[(2-dimethylamino-ethylamino)-methyl]-pyrimidin-4-yloxy}-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-methyl-5-[2-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-{6-[(2-dimethylamino-ethylamino)-methyl]-pyrimidin-4-yloxy}-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-(6-{[(2-dimethylamino-ethyl)-methyl-amino]-methyl}-pyrimidin-4-yloxy)-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(1-methyl-piperidin-4-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(1-methyl-pipendin-4-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(pyrrolidin-3-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[2-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-chloro-4-methyl-5-[2-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[6-(1-methyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[6-(piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[2-(1-methyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-{2-[methyl-(1-methyl-piperidin-4-yl)-amino]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-[methyl-(1-methyl-piperidin-4-yl)-amino]-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[2-(piperidin-4-ylamino)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(2-piperidin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-{6-[(2-dimethylamino-ethylamino)-methyl]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(6-{[(2-dimethylamino-ethyl)-methyl-amino]-methyl}-pyrimidin-4-yl oxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(6-piperazin-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(6-piperidin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[6-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[6-(1-methyl-piperidin-4-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[2-(1-methyl-piperidin-4-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-3-[2-(trans-4-dimethylamino-cyclohexylamino)-pyrimidin-4-yloxy]-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-{2-[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-{6-[methyl-(1-methyl-pyrrolidin-3-yl)-amino]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[2-(4-methyl-[1,4]diazepan-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(2-{[(2-dimethylamino-ethyl)-methyl-amino]methyl}-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-{2-[(2-dimethylamino-ethylamino)-methyl]-pyrimidin-4-yloxy}-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-[6-(4-methyl-[1,4]diazepan-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(2-piperazin-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-chloro-3-(6-[1,4]diazepan-1-ylmethyl-pyrimidin-4-yloxy)-benzamide;

N-(5-tert-butyl-3-methanesulphonyl-2-methoxy-phenyl)-4-methyl-3-(2-pipendin-4-ylmethyl-pyrimidin-4-yloxy)-benzamide;

3-(2-azepan-4-ylmethyl-pyrimidin-4-yloxy)-N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[2-(1-methyl-azepan-4-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

3-(6-azepan-4-ylmethyl-pyrimidin-4-yloxy)-N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-benzamide;

N-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-4-methyl-3-[6-(1-methyl-azepan-4-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-hydroxymethyl-2-methoxy-phenyl)-4-methyl-3-[2-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

N-(5-tert-butyl-3-methanesulphinyl-2-methoxy-phenyl)-4-methyl-3-[2-(4-methyl-piperazin-1-ylmethyl)-pyrimidin-4-yloxy]-benzamide;

or a tautomer, stereoisomer or mixture thereof or a physiologically acceptable salt thereof.

26. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt and one or more inert carriers, preservatives and/or diluents.

27. A process for preparing a compound of the formula I according to claim 1 comprising

reacting a compound of formula II,

wherein R 1 to R 4 , X and Y have the meanings given in claim 1 and LG denotes fluorine, chlorine, bromine, cyano, C 1-10 -alkoxy, C 1-6 -alkylsulphanyl, C 2-4 -alkenyl-oxy, C 2-4 -alkynyloxy, benzotriazol-1-yloxy, [1.2.3]triazolo[4,5-b]pyridin-3-yloxy, C 5-10 -heteroaryl (linked to II via N), succinyl-N-oxy, C 1-4 -alkylcarbonyloxy, di-(C 1-4 -alkyl)aminocarbonyloxy, pyrrol-1-ylcarbonyloxy, piperidin-1-yl-carbonyloxy, morpholin-4-ylcarbonyloxy, tri-(C 1-4 -alkyl)carbamimidoyloxy, N,N,N′,N′-tetra-(C 1-4 -alkyl)-uronium-O-yl, N,N′-dicyclohexyluron-O-yl, N-(3-dimethylaminopropyl)-N′-ethyl-uronyl, di-(C 1-4 -alkyloxy)-phosphoryloxy, bis(di-C 1-4 -alkylamino)-phosphoryloxy, dipyrrolidinyl-phosphoryloxy, C 6-10 -arylsulphanyl, C 5-10 -heteroarylsulphanyl, C 6-10 -aryloxy or C 5-10 -heteroaryloxy,

wherein all the alkyl, alkenyl and alkynyl groups mentioned in the definition may be mono- or polysubstituted by fluorine, chlorine, C 1-3 -alkyl and/or C 1-3 ″ alkoxy,

wherein all the aryl groups mentioned in the definition represent phenyl or naphthyl and all the heteroaryl groups represent pyridinyl, pyrimidinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl or tetrazolyl, which, both aryl and heteroaryl groups, are optionally mono- or polysubstituted by identical or different groups selected from among fluorine, chlorine, bromine, C 1-3 -alkyl, C 1-3 -alkyloxy, nitro, cyano and di-(C 1-3 -alkyl)amino,

with an aniline of formula

wherein R 5 , R 6 and R 7 have the meanings given in claim 1 ,

optionally in the presence of Triethylamine, pyridine, ethyldiisopropylamine, 4-dimethylaminopyridine, potassium carbonate or 1-hydroxybenzotriazole; and

optionally any protecting group used in the reactions described hereinbefore under a) and b) is cleaved again, and/or

optionally a compound of general formula I thus obtained is resolved into its stereoisomers and/or

optionally a compound of general formula I thus obtained is converted into the salts thereof.

28. A process for preparing a compound of the formula I according to claim 1 comprising reacting a compound of general formula III

wherein R 1 , R 3 , R 5 , R 6 and R 7 have the meanings given in claim 1 ,

with a compound of formula IV

wherein R 2 and R 4 have the meanings given in claim 1 and LG denotes a leaving group, in particular LG denotes

F, Cl, Br, I, O—C 1-6 -alkyl, O—C 6-10 -aryl, S(O) n —, —C 1-4 -alkyl, S(O) m —C 5-10 -aryl, OSO 2 —C 1-4 -alkyl, OSO 2 —C 6-10 -aryl, NO 2 ,

wherein all the above-mentioned alkyl groups are optionally mono- or polysubstituted by fluorine, C 1-3 -alkyl and/or C 1-3 -alkoxy, and

wherein all the above-mentioned aryl groups represent phenyl or naphthyl, which may optionally be mono- or polysubstituted by identical or different groups selected from fluorine, chlorine, C 1-3 -alkyl, C 1-3 -alkyloxy, nitro and cyano,

wherein n and m independently of one another may be 0, 1 or 2,

in the presence of a base NaH, KH, KOtBu, NaOtBu, NaOMe, NaOEt, NaOiPr, KF, K 2 CO 3 , Cs 2 CO 3 , pyridine, 4-dimethylaminopyridine, NEt 3 or EtNiPr 2 ,

optionally in the presence of a catalyst A Cu or Pd complex; and

optionally any protecting group used in the reactions described hereinbefore under a) and b) is cleaved again, and/or

optionally a compound of general formula I thus obtained is resolved into its stereoisomers and/or

optionally a compound of general formula I thus obtained is converted into the salts thereof.

29. A method of treating COPD or asthma comprising administering to a patient a therapeutically effective amount of a compound according to claim 1 or a physiologically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2011
From: WAGNER, HOLGER; LANGKOPF, ELKE; HIMMELSBACH, FRANK; GOEGGEL, ROLF; JUNG, BIRGIT
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 026088/0816 →
Priority Claims (1)
EP 08163525 · Sep 2, 2008 · regional
Continuity (1)
Related Publication 20120108572A1 · May 3, 2012